|
[Related PubMed/MEDLINE] Total Number of Papers: 812
|
|
|
[Display Entries]
|
>> all entries
|
|
[Entries Per Page]
|
per page
|
|
Page Control
|
|
Page: of |
|
|
|
No. |
Year |
Title |
Co-occurring Abbreviation |
1 |
2023 |
BET Inhibitors Induce p53-Independent Growth Arrest in HCT116 Cells via Epigenetic Control of the E2F1/c-MYC Axis. |
BET, ChIP |
2 |
2022 |
"RB-reactivator screening" as a novel cell-based assay for discoveries of molecular targeting agents including the first-in-class MEK inhibitor trametinib (trade name: Mekinist). |
FDA |
3 |
2022 |
Case of Glioblastoma Multiforme in the Left Temporoparietal Region of the Brain. |
MGMT, PET, PI3K, RAS, RTK |
4 |
2022 |
CDK4/6 inhibitor resistance: A bibliometric analysis. |
CDKs, HER2 |
5 |
2022 |
CDK4/6 initiates Rb inactivation and CDK2 activity coordinates cell-cycle commitment and G1/S transition. |
CDKs |
6 |
2022 |
Endothelial cyclin I reduces vulnerability to angiotensin II-induced vascular remodeling and abdominal aortic aneurysm risk. |
AAA, Ang, Ccni, Cdk5, DHFR, E2f1, GEO, WT |
7 |
2022 |
Functions and Interactions of Mammalian KDM5 Demethylases. |
2OG, HDAC |
8 |
2022 |
Hypoxia represses early responses of prostate and renal cancer cells to YM155 independent of HIF-1alpha and HIF-2alpha. |
HIF, HIF-X, mTORC1, rS6 |
9 |
2022 |
Inhibiting ERK5 overcomes breast cancer resistance to anti-HER2 therapy by targeting the G1/S cell cycle transition. |
ERK5, HER2 |
10 |
2022 |
Knockdown of mitochondrial threonyl-tRNA synthetase 2 inhibits lung adenocarcinoma cell proliferation and induces apoptosis. |
aaRSs, LUAD, mROS, mtDNA, OS, TARS, TARS2 |
11 |
2022 |
Lidocaine enhances the efficacy of palbociclib in triple-negative breast cancer. |
CDK |
12 |
2022 |
Regulation of p27 (Kip1) by Ubiquitin E3 Ligase RNF6. |
RNF6 |
13 |
2022 |
RNA polymerase I inhibition induces terminal differentiation, growth arrest, and vulnerability to senolytics in colorectal cancer cells. |
APC, CRC, MIZ1, rDNA |
14 |
2022 |
Structural basis for tunable affinity and specificity of LxCxE-dependent protein interactions with the retinoblastoma protein family. |
--- |
15 |
2022 |
The HPV16E7 Affibody as a Novel Potential Therapeutic Agent for Treating Cervical Cancer Is Likely Internalized through Dynamin and Caveolin-1 Dependent Endocytosis. |
pRb |
16 |
2022 |
The SREBP-dependent regulation of cyclin D1 coordinates cell proliferation and lipid synthesis. |
SREBP |
17 |
2022 |
Transmembrane protein 121 as a novel inhibitor of cervical cancer metastasis. |
Bcl-2, CCK-8, CESC, TIMER, TMEM121 |
18 |
2021 |
Age-related neurodegeneration and cognitive impairments of NRMT1 knockout mice are preceded by misregulation of RB and abnormal neural stem cell development. |
NSC |
19 |
2021 |
Anti-Atherosclerotic Effect of Gossypetin on Abnormal Vascular Smooth Muscle Cell Proliferation and Migration. |
CDK, GTIN, MMP, NF-kappaB, PKB, ROS, VSMCs |
20 |
2021 |
Atypical E2Fs either Counteract or Cooperate with RB during Tumorigenesis Depending on Tissue Context. |
--- |
21 |
2021 |
Biomarkers of Response to Etoposide-Platinum Chemotherapy in Patients with Grade 3 Neuroendocrine Neoplasms. |
EP, G3 NEN, NET, ORR |
22 |
2021 |
Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer. |
BLCA, CAM, PARP |
23 |
2021 |
Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment. |
CDKs |
24 |
2021 |
Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma. |
HCC |
25 |
2021 |
Down-regulation of lncRNA MEG3 promotes chronic low dose cadmium exposure-induced cell transformation and cancer stem cell-like property. |
Cd, CSC, DMR, DNMTs, lncRNA |
26 |
2021 |
In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach. |
CI, DOX, Imax, PD, PK, pRb, TNBC, TTP |
27 |
2021 |
p21 produces a bioactive secretome that places stressed cells under immunosurveillance. |
PASP |
28 |
2021 |
Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer. |
CDK, ER, FDA, HER2, TNBC |
29 |
2021 |
Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network. |
GTE, NECs, OS, PE |
30 |
2021 |
Purification of Cyclin-Dependent Kinase Fusion Complexes for In Vitro Analysis. |
CDK |
31 |
2021 |
Recent Understanding and Future Directions of Recurrent Corticotroph Tumors. |
ACTH, CABLES1, CD, CDKs, CTs, EGFR, HDAC2, Hsp90, SCT, TR4, USP |
32 |
2021 |
Redefining IL11 as a regeneration-limiting hepatotoxin and therapeutic target in acetaminophen-induced liver injury. |
AILI, ERK, IL-11, Il11ra1, JNK, NOX4, PCNA, rhIL11 |
33 |
2021 |
Retinoblastoma protein promotes uterine epithelial cell cycle arrest and necroptosis for embryo invasion. |
CCA |
34 |
2021 |
SUMOylation regulates Rb hyperphosphorylation and inactivation in uveal melanoma. |
SUMO, UM |
35 |
2021 |
The mechanisms involved in the resistance of estrogen receptor-positive breast cancer cells to palbociclib are multiple and change over time. |
ER |
36 |
2021 |
The Retinoblastoma Tumor Suppressor Is Required for the NUP98-HOXA9-Induced Aberrant Nuclear Envelope Phenotype. |
LAP2alpha, NE, NHA9 |
37 |
2020 |
A Circular RNA from the MDM2 Locus Controls Cell Cycle Progression by Suppressing p53 Levels. |
circRNAs, siRNAs |
38 |
2020 |
A Cyclin D1-Specific Single-Chain Variable Fragment Antibody that Inhibits HepG2 Cell Growth and Proliferation. |
ER, HCC, scFv |
39 |
2020 |
A genome-wide association study for highly sensitive cardiac troponin T levels identified a novel genetic variation near a RBAK-ZNF890P locus in the Japanese general population. |
CVD, GWAS, hs-cTnT, KRAB, ZNF890P |
40 |
2020 |
A highly stable RNA aptamer probe for the retinoblastoma protein in live cells. |
--- |
41 |
2020 |
A masked initiation region in retinoblastoma protein regulates its proteasomal degradation. |
HPV |
42 |
2020 |
A pipecolic acid-rich branched cyclic depsipeptide ulleungamide C from a Streptomyces species induces G0/G1 cell cycle arrest in promyelocytic leukemia cells. |
CDK4 |
43 |
2020 |
Cell growth dilutes the cell cycle inhibitor Rb to trigger cell division. |
--- |
44 |
2020 |
Cyclin D-CDK4/6 functions in cancer. |
CDKs |
45 |
2020 |
Effect of Yanggan Jiedu Sanjie formula on human hepatocellular carcinoma Bel-7402 cells. |
CDKN1a, SA-beta-gal, YGJDSJ |
46 |
2020 |
Hypothesis: Retinoblastoma protein inactivation mediates effects of histone deacetylase inhibitor-induced Wnt hyperactivation in colorectal cancer cells. |
--- |
47 |
2020 |
In Vitro Effect and Mechanism of Action of Ergot Alkaloid Dihydroergocristine in Chemoresistant Prostate Cancer Cells. |
AMPK, DHECS, E2F1, Mcl-1, MDM2, NF-B, PARP, PCa |
48 |
2020 |
Inhibition of the CDK4/6-Cyclin D-Rb Pathway by Ribociclib Augments Chemotherapy and Immunotherapy in Renal Cell Carcinoma. |
RCC |
49 |
2020 |
p16 promotes proliferation in cervical carcinoma cells through CDK6-HuR-IL1A axis. |
HPV |
50 |
2020 |
Programmed cell death protein 1/programmed death ligand 1 but not HER2 is a potential therapeutic target in gastric neuroendocrine carcinoma. |
CPS, NEC, PD-L1, TIL |
51 |
2020 |
RAGE acts as an oncogenic role and promotes the metastasis of human lung cancer. |
RAGE, TAM |
52 |
2020 |
Retinoblastoma protein expression and its predictors in triple-negative breast cancer. |
AR, CDK, TNBC |
53 |
2020 |
Rosiglitazone ameliorates senescence and promotes apoptosis in ovarian cancer induced by olaparib. |
CCK-8, SA-beta-gal, SASP |
54 |
2020 |
Small Molecule CDK Inhibitors for the Therapeutic Management of Cancer. |
CDKs |
55 |
2020 |
SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability. |
CDK |
56 |
2020 |
Stable expansion of high-grade serous ovarian cancer organoids requires a low-Wnt environment. |
FT, HGSOC |
57 |
2020 |
The NSD2/WHSC1/MMSET methyltransferase prevents cellular senescence-associated epigenomic remodeling. |
--- |
58 |
2019 |
A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach. |
CDK4 |
59 |
2019 |
A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort. |
CNS, CSF, PFS |
60 |
2019 |
Antiproliferative activity of vanadium compounds: effects on the major malignant melanoma molecular pathways. |
ERK, MAPK, MM, ROS, VN |
61 |
2019 |
ARID1A prevents squamous cell carcinoma initiation and chemoresistance by antagonizing pRb/E2F1/c-Myc-mediated cancer stemness. |
CDKs, SCC |
62 |
2019 |
Cyclin D-CDK4 relieves cooperative repression of proliferation and cell cycle gene expression by DREAM and RB. |
CDK4 |
63 |
2019 |
DeltaNp63alpha modulates phosphorylation of p38 MAP kinase in regulation of cell cycle progression and cell growth. |
MKP3, p38 MAPK |
64 |
2019 |
E2F1 transactivates IQGAP3 and promotes proliferation of hepatocellular carcinoma cells through IQGAP3-mediated PKC-alpha activation. |
HCC |
65 |
2019 |
Endothelial retinoblastoma protein reduces abdominal aortic aneurysm development via promoting DHFR/NO pathway-mediated vasoprotection. |
AAA, Ang II, CVD, DHFR |
66 |
2019 |
MSK2 promotes proliferation and tumor formation in squamous cervical cancer via PAX8/RB-E2F1/cyclin A2 axis. |
MSK2, PAX8, SCC |
67 |
2019 |
Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells. |
CDKs, HCC |
68 |
2019 |
PROTACs suppression of CDK4/6, crucial kinases for cell cycle regulation in cancer. |
--- |
69 |
2019 |
RB, p130and p107 differentially repress G1/S and G2/M genes after p53 activation. |
--- |
70 |
2019 |
RB1 Deletion in Retinoblastoma Protein Pathway-Disrupted Cells Results in DNA Damage and Cancer Progression. |
--- |
71 |
2019 |
Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma. |
CSF, GBM |
72 |
2019 |
ZBTB7A Mediates the Transcriptional Repression Activity of the Androgen Receptor in Prostate Cancer. |
AR, CRPC |
73 |
2018 |
Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling. |
CDX, ES, PDX |
74 |
2018 |
Bufadienolides from Venenum Bufonis Inhibit mTOR-Mediated Cyclin D1 and Retinoblastoma Protein Leading to Arrest of Cell Cycle in Cancer Cells. |
eIF4E, mTOR, S6K1 |
75 |
2018 |
Class I and II Histone Deacetylase Inhibitors Differentially Regulate Thermogenic Gene Expression in Brown Adipocytes. |
HDACIs |
76 |
2018 |
Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer. |
ASCL1, EGFR, NSCLC, SCLC, TKI |
77 |
2018 |
Control of the Restriction Point by Rb and p21. |
CDK |
78 |
2018 |
Cooperative p16 and p21 action protects female astrocytes from transformation. |
CDK |
79 |
2018 |
Cyclic mechanical tension reinforces DNA damage and activates the p53-p21-Rb pathway to induce premature senescence of nucleus pulposus cells. |
CMT, IVD, NP |
80 |
2018 |
Decreased SUMOylation of the retinoblastoma protein in keratinocytes during the pathogenesis of vitiligo. |
CDK, PCNA, pRb, SAE1, SUMO |
81 |
2018 |
Discovery of rafoxanide as a dual CDK4/6 inhibitor for the treatment of skin cancer. |
--- |
82 |
2018 |
Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy. |
PDX-TNBC, TNBC |
83 |
2018 |
Hyper-phosphorylation of Rb S249 together with CDK5R2/p39 overexpression are associated with impaired cell adhesion and epithelial-to-mesenchymal transition: Implications as a potential lung cancer grading and staging biomarker. |
NSCLC, SCC |
84 |
2018 |
Involvement of the STAT5-cyclin D/CDK4-pRb pathway in beta-cell proliferation stimulated by prolactin during pregnancy. |
p-Rb, PRL, Rb-KO |
85 |
2018 |
Methylation‑associated silencing of miR‑128 promotes the development of esophageal cancer by targeting COX‑2 in areas with a high incidence of esophageal cancer. |
DNMT, ESCC, ZD |
86 |
2018 |
MYC Releases Early Reprogrammed Human Cells from Proliferation Pause via Retinoblastoma Protein Inhibition. |
--- |
87 |
2018 |
Neuropilin 1 Mediates Keratinocyte Growth Factor Signaling in Adipose-Derived Stem Cells: Potential Involvement in Adipogenesis. |
ASCs, KGF, NRP-1 |
88 |
2018 |
PIN1 in Cell Cycle Control and Cancer. |
CDKs |
89 |
2018 |
Suppression of Cell Growth, Migration and Drug Resistance by Ethanolic Extract of Antrodia cinnamomea in Human Lung Cancer A549 Cells and C57BL/6J Allograft Tumor Model. |
AMPK, EEAC, MMP, mTOR |
90 |
2018 |
[Pharmacological profile and clinical findings of palbociclib (IBRANCE capsule 25 mg/125 mg)]. |
CDK, ER, PFS |
91 |
2017 |
Activation of PERK-Nrf2 oncogenic signaling promotes Mdm2-mediated Rb degradation in persistently infected HCV culture. |
ER, HCC, HCV |
92 |
2017 |
Breviscapine (BVP) inhibits prostate cancer progression through damaging DNA by minichromosome maintenance protein-7 (MCM-7) modulation. |
BVP, MCM-7 |
93 |
2017 |
Conservation and divergence of C-terminal domain structure in the retinoblastoma protein family. |
CMs, CTDs |
94 |
2017 |
Dosing time dependent in vitro pharmacodynamics of Everolimus despite a defective circadian clock. |
EV, mTOR |
95 |
2017 |
Effects of sorafenib and an adenylyl cyclase activator on in vitro growth of well-differentiated thyroid cancer cells. |
AC, cAMP, CDK4, MAPK, RTKs, TSH |
96 |
2017 |
Functions of the Tumor Suppressors p53 and Rb in Actin Cytoskeleton Remodeling. |
--- |
97 |
2017 |
Host cell transcriptome modification upon exogenous HPV16 L2 protein expression. |
--- |
98 |
2017 |
HPV/E7 induces chemotherapy-mediated tumor suppression by ceramide-dependent mitophagy. |
HNSCC, HPV |
99 |
2017 |
Inhibition of estrogen related receptor alpha attenuates vascular smooth muscle cell proliferation and migration by regulating RhoA/p27Kip1 and beta-Catenin/Wnt4 signaling pathway. |
RASMCs, VSMCs |
100 |
2017 |
LSD1 promotes S-phase entry and tumorigenesis via chromatin co-occupation with E2F1 and selective H3K9 demethylation. |
LSD1 |
|